Intellia Flags In Vivo CRISPR Knockout Platform As Key Priority For 2023

 
• By Ayisha Sharma

After ending 2022 with more than $1bn in cash, the US firm is keen to validate its in vivo approach to gene therapy with investigational new drug applications and pivotal trials lined up for two core rare disease programs.  

Blocks with numbers on them being stacked on each other by hand, yellow background
Intellia Is Also Working On A Gene Insertion Technology • Source: Shutterstock

More from Business

More from Scrip